A heparin-mimicking polymer conjugate stabilizes basic fibroblast growth factor

Nature Chemistry

Volumn 5, Issue 3, 2013, Pages 221-227

  Nguyen, Thi H ^a   Kim, Sung Hye ^a   Decker, Caitlin G ^a   Wong, Darice Y ^a   Loo, Joseph A ^a   Maynard, Heather D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMIMETIC MATERIAL; DRUG DERIVATIVE; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HEPARIN; MACROGOL DERIVATIVE; METHACRYLIC ACID DERIVATIVE; POLYETHYLENE GLYCOL METHACRYLATE; POLYSTYRENE DERIVATIVE; POLYSTYRENESULFONIC ACID;

ARTICLE; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; FIBROBLAST; HUMAN; PROTEIN STABILITY; SYNTHESIS;

BIOMIMETIC MATERIALS; CELLS, CULTURED; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HEPARIN; HUMANS; METHACRYLATES; MODELS, MOLECULAR; POLYETHYLENE GLYCOLS; POLYSTYRENES; PROTEIN STABILITY; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1;

MLCS; MLOWN;

EID: 84875431729     PISSN: 17554330     EISSN: 17554349     Source Type: Journal    
DOI: 10.1038/nchem.1573     Document Type: Article

References (50)

1. Abuchowski, A., Vanes, T., Palczuk, N. C. & Davis, F. F. Alteration of immunological properties of bovine serum-albumin by covalent attachment of polyethylene-glycol. J. Biol. Chem. 252, 3578-3581 (1977).
2. Duncan, R. The dawning era of polymer therapeutics. Nature Rev. Drug Discov. 2, 347-360 (2003).
3. Alconcel, S. N. S., Baas, A. S. & Maynard, H. D. FDA-approved poly(ethylene glycol)-protein conjugate drugs. Polym. Chem. 2, 1442-1448 (2011).
4. Keefe, A. J. & Jiang, S. Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity. Nature Chem. 4, 59-63 (2012).
5. Mancini, R. J., Lee, J. & Maynard, H. D. Trehalose glycopolymers for stabilization of protein conjugates to environmental stressors. J. Am. Chem. Soc. 134, 8474-8479 (2012).
6. Capila, I. & Linhardt, R. J. Heparin-protein interactions. Angew. Chem. Int. Ed. 41, 391-412 (2002).
7. Cardin, A. D. & Weintraub, H. J. R. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9, 21-32 (1989).
8. Slack, J. M. W., Darlington, B. G., Heath, J. K. & Godsave, S. F. Mesoderm induction in early xenopus embryos by heparin-binding growth-factors. Nature 326, 197-200 (1987).
9. Cross, M. J. & Claesson-Welsh, L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22, 201-207 (2001).
10. Kawai, K., Suzuki, S., Tabata, Y., Ikada, Y. & Nishimura, Y. Accelerated tissue regeneration through incorporation of basic fibroblast growth factor-impregnated gelatin microspheres into artificial dermis. Biomaterials 21, 489-499 (2000).
11. Canalis, E., Centrella, M. & McCarthy, T. Effects of basic fibroblasat growth-factor on bone-formation in vitro. J. Clin. Invest. 81, 1572-1577 (1988).
12. Timmer, M. et al. Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion. J. Neurosci. 27, 459-471 (2007).
13. Levenstein, M. E. et al. Basic fibroblast growth factor support of human embryonic stem cell self-renewal. Stem Cells 24, 568-574 (2006).
14. Barrientos, S., Stojadinovic, O., Golinko, M. S., Brem, H. & Tomic-Canic, M. Growth factors and cytokines in wound healing. Wound Repair Regen. 16, 585-601 (2008).
15. Shipley, G. D., Keeble, W. W., Hendrickson, J. E., Coffey, R. J. & Pittelkow, M. R. Growth of normal human keratinocytes and fibroblasts in serum-free medium is stimulated by acidic and basic fibroblast growth-factor. J. Cell Physiol. 138, 511-518 (1989).
16. Pittelkow, M. R. & Shipley, G. D. Serum-free culture of normal human melanocytes-growth-kinetics and growth-factor requirements. J. Cell Physiol. 140, 565-576 (1989).
17. Edelman, E. R., Mathiowitz, E., Langer, R. & Klagsbrun, M. Controlled and modulated release of basic fibroblast growth-factor. Biomaterials 12, 619-626 (1991).
18. Whalen, G. F., Shing, Y. & Folkman, J. The fate of intravenously administered bFGF and the effect of heparin. Growth Factors 1, 156-164 (1989).
19. Richard, J. L. et al. Effect of topical basic fibroblast growth-factor on the healing of chronic diabetic neuropathic ulcer of the foot-a pilot, randomized, double-blind, placebo-controlled study. Diabetes Care 18, 64-69 (1995).
20. Gospodarowicz, D. & Cheng, J. Heparin protects basic and acidic FGF from inactivation. J. Cell Physiol. 128, 475-484 (1986).
21. Sakiyama-Elbert, S. E. et al. in Comprehensive Biomaterials Vol. 4 (eds Ducheyne, P.) Ch. 420, 333-339 (Elsevier, 2011).
22. Cariou, R., Harousseau, J. L. & Tobelem, G. Inhibition of human-endothelial cell-proliferation by heparin and steroids. Cell Biol. Int. Rep. 12, 1037-1047 (1988).
23. Ferrao, A. V. & Mason, R. M. The effect of heparin on cell-proliferation and type-I collagen-synthesis by adult human dermal fibroblasts. Biochim. Biophys. Acta 1180, 225-230 (1993).
24. Liekens, S. et al. Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds. Mol. Pharmacol. 56, 204-213 (1999).
25. Guan, R., Sun, X. L., Hou, S. J., Wu, P. Y. & Chaikof, E. L. A glycopolymer chaperone for fibroblast growth factor-2. Bioconj. Chem. 15, 145-151 (2004).
26. Christman, K. L. et al. Nanoscale growth factor patterns by immobilization on a heparin-mimicking polymer. J. Am. Chem. Soc. 130, 16585-16591 (2008).
27. Kolodziej, C. M. et al. Combination of integrin-binding peptide and growth factor promotes cell adhesion on electron-beam-fabricated patterns. J. Am. Chem. Soc. 134, 247-255 (2012).
28. Wu, X., Li, X., Zeng, Y., Zheng, Q. & Wu, S. Site-directed PEGylation of human basic fibroblast growth factor. Protein Expr. Purif. 48, 24-27 (2006).
29. Wu, X. et al. Purification and modification by polyethylene glycol of a new human basic fibroblast growth factor mutant-hbFGFSer25, 87, 92. J. Chromatogr. A 1161, 51-55 (2007).
30. DeLong, S. A., Moon, J. J. & West, J. L. Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration. Biomaterials 26, 3227-3234 (2005).
31. Kang, C. E., Tator, C. H. & Shoichet, M. S. Poly(ethylene glycol) modification enhances penetration of fibroblast growth factor 2 to injured spinal cord tissue from an intrathecal delivery system. J. Control. Rel. 144, 25-31 (2010).
32. Huang, Z. F. et al. Solid-phase N-terminus PEGylation of recombinant human fibroblast growth factor 2 on heparin-sepharose column. Bioconj. Chem. 23, 740-750 (2012).
33. Sumerlin, B. S. Proteins as initiators of controlled radical polymerization: grafting-from via ATRP and RAFT. ACS Macro Lett. 1, 141-145 (2012).
34. Tolstyka, Z. & Maynard, H. D. in Comprehensive Polymer Science Vol. 9 (eds Matyjaszewski, K. & Möller, M.) Ch. 17, 317-337 (Elsevier, 2012).
35. Moad, G., Rizzardo, E. & Thang, S. H. Living radical polymerization by the RAFT process-a third update. Aust. J. Chem. 65, 985-1076 (2012).
36. Chang, C. W., Bays, E., Tao, L., Alconcel, S. N. S. & Maynard, H. D. Differences in cytotoxicity of poly(PEGA)s synthesized by reversible addition-fragmentation chain transfer polymerization. Chem. Commun. 3580-3582 (2009).
37. Maynard, H. D. & Hubbell, J. A. Discovery of a sulfated tetrapeptide that binds to vascular endothelial growth factor. Acta Biomater. 1, 451-459 (2005).
38. Tao, L. et al. Synthesis of maleimide-end-functionalized star polymers and multimeric protein-polymer conjugates. Macromolecules 42, 8028-8033 (2009).
39. Loo, J. A. et al. Electrospray ionization mass spectrometry and ion mobility analysis of the 20S proteasome complex. J. Am. Soc. Mass Spectr. 16, 998-1008 (2005).
40. Gethin, G. The significance of surface pH in chronic wounds. Wounds UK 3, 52-56 (2007).
41. Mohammadi, M. et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276, 955-960 (1997).
42. Mohammadi, M. et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17, 5896-5904 (1998).
43. Johnson, D. E., Lu, J., Chen, H., Werner, S. & Williams, L. T. The human fibroblast growth-factor receptor genes-a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their 3rd immunoglobulin domain. Mol. Cell. Biol. 11, 4627-4634 (1991).
44. Schlessinger, J. et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6, 743-750 (2000).
45. Plotnikov, A. N., Schlessinger, J., Hubbard, S. R. & Mohammadi, M. Structural basis for FGF receptor dimerization and activation. Cell 98, 641-650 (1999).
46. Ornitz, D. M. & Leder, P. Ligand specificity and heparin dependence of fibroblast growth-factor receptor-1 and receptor-3. J. Biol. Chem. 267, 16305-16311 (1992).
47. Fishburn, C. S. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J. Pharm. Sci. 97, 4167-4183 (2008).
48. Pasut, G. & Veronese, F. M. Polymer-drug conjugation, recent achievements and general strategies. J. Pharm. Sci. 32, 933-961 (2007).
49. Khondee, S., Olsen, C. M., Zeng, Y. H., Middaugh, C. R. & Berkland, C. Noncovalent PEGylation by polyanion complexation as a means to stabilize keratinocyte growth factor-2 (KGF-2). Biomacromolecules 12, 3880-3894 (2011).
50. Griffith, B. R., Allen, B. L., Rapraeger, A. C. & Kiessling, L. L. A polymer scaffold for protein oligomerization. J. Am. Chem. Soc. 126, 1608-1609 (2004).